

## FORM 9

### **NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

**(or securities convertible or exchangeable into listed securities<sup>1</sup>)**

Name of Listed Issuer:

Symbol(s):

<b>BioNxt Solutions Inc. (the "Issuer").</b>	BNXT
--	------

Date: **April 15, 2024**

Is this an updating or amending Notice:  Yes  No

If yes provide date(s) of prior Notices: N/A.

Issued and Outstanding Securities of Issuer Prior to Issuance: **109,269,065**.

#### **Pricing**

Date of news release announcing proposed issuance: **November 13, 2023** or

Date of confidential request for price protection: N/A.

Closing Market Price on Day Preceding the news release: **\$0.32 (November 10, 2023)**  
or

Day preceding request for price protection: N/A

#### **Closing**

Number of securities to be issued: **250,000 common shares in the capital of the Issuer (each, a "Common Share")**

Issued and outstanding securities following issuance: **109,519,065**

#### **Instructions:**

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction

---

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

March 2023  
Page 1

6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to [listings@thecse.com](mailto:listings@thecse.com) with an appendix that includes the information in Table 1B for ALL places.

**Part 1. Private Placement**

**Table 1A – Summary**

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
Total number of purchasers:			
Total dollar value of distribution in all jurisdictions:			

**Table 1B – Related Persons**

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
N/A							

<sup>1</sup>An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \_\_\_\_\_.
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. The common shares are being issued in connection with \_\_\_\_\_.
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: \_\_\_\_\_.
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.
5. Description of securities to be issued:
  - (a) Class \_\_\_\_\_.
  - (b) Number \_\_\_\_\_.
  - (c) Price per security \_\_\_\_\_.
  - (d) Voting rights \_\_\_\_\_.
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
  - (a) Number \_\_\_\_\_.
  - (b) Number of securities eligible to be purchased on exercise of warrants (or options) \_\_\_\_\_  
\_\_\_\_\_.
  - (c) Exercise price \_\_\_\_\_.
  - (d) Expiry date \_\_\_\_\_.
7. Provide the following information if debt securities are to be issued:
  - (a) Aggregate principal amount \_\_\_\_\_.
  - (b) Maturity date \_\_\_\_\_.
  - (c) Interest rate \_\_\_\_\_.
  - (d) Conversion terms \_\_\_\_\_.
  - (e) Default provisions \_\_\_\_\_.

---

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF  
LISTED SECURITIES**

March 2023  
Page 3

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): \_\_\_\_\_ .
  - (b) Cash \_\_\_\_\_ .
  - (c) Securities \_\_\_\_\_ .
  - (d) Other \_\_\_\_\_ .
  - (e) Expiry date of any options, warrants etc. \_\_\_\_\_ .
  - (f) Exercise price of any options, warrants etc. \_\_\_\_\_ .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship.
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).  
\_\_\_\_\_ .
11. State whether the private placement will result in a change of control or if the issuance will materially affect control of the Issuer.  
\_\_\_\_\_ .
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_ .
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

---

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

March 2023  
Page 4

## Part 2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: **The acquisition by the Issuer of 100% of the intellectual property rights arising out of the joint development of an oral dissolvable (“ODF”) drug reformulation using the active pharmaceutical ingredient Cladribine from Entomus GmbH, a German-based pharmaceutical developer (the “Developer”)**
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: **On October 29, 2023, the Issuer entered into a joint development agreement (the “Agreement”) with the Developer, an arm’s length party for the acquisition of 100% of the intellectual property rights arising out of the joint development of an ODF drug reformulation using the active pharmaceutical ingredient Cladribine. Pursuant to the Agreement, as consideration for the intellectual property rights and development contributions, the Issuer agreed to pay the following consideration to the Developer: (a) a cash fee of €150,000, payable in two equal instalments; (b) a monthly management fee of €15,000, which will be increased to €20,000 upon completion of the pilot study related to the Cladribine ODF (the “Management Fee”); (c) license royalties in the event the Issuer grants licenses to any product using the Cladribine ODF or other film developed in performance of the joint development activities (the “License Royalties”); and (d) (i) 100,000 Common Shares at a deemed price of \$0.50 per Common Share, and (ii) up to 2,500,000 additional Common Shares at a deemed price of \$0.50 per Common Share (or such other price permitted by the policies of the Canadian Securities Exchange) upon the occurrence of certain specified milestones set out in the Agreement (the “Additional Consideration Shares”).**
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
  - (a) Total aggregate consideration in Canadian dollars: **\$3,244,305<sup>1</sup>**

---

<sup>1</sup> This figure assumes: (i) the minimum monthly Management Fee was paid for the first five months and the maximum monthly Management Fee is paid for the remainder of the Agreement; (ii) all of the Additional Consideration Shares are issued at \$0.50 per Additional Consideration Share; and (iii) the Bank of Canada exchange rate as at October 30, 2023, will apply throughout the term of the Agreement. This figure excludes any License Royalties that may be payable in the future.

- (b) Cash: \$220,110 cash fee (conversion to Cdn\$ as at October 30, 2023), payable in two equal instalments, a monthly management fee of \$22,011 (conversion to Cdn\$ as at October 30, 2023), which will be increased to \$29,348 (conversion to Cdn\$ as at October 30, 2023) upon completion of the pilot study related to the Cladribine ODF, and license fees in the event the Issuer grants licenses to any product using the Cladribine ODF or other film development in performance of the joint development activities .
- (c) Securities (including options, warrants etc.) and dollar value: 250,000 Common Shares at a deemed price of \$0.50 per Common Share, and up to 2,350,000 additional Common Shares upon the occurrence of certain specified milestones set out in the Agreement .
- (d) Other: N/A .
- (e) Expiry date of options, warrants, etc. if any: N/A .
- (f) Exercise price of options, warrants, etc. if any: N/A .
- (g) Work commitments: \_\_\_\_\_ .
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc). The purchase price was determined by arm's-length negotiation.
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: N/A .
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer <sup>(1)</sup>
Entomus GmbH (Oleksandr Zabudkin, Mark Zabudkin, Angelo Columbo)	250,000 Common Shares	\$0.50	N/A	2.24 of NI 45-106 [Employee, executive officer, director and consultant]	Nil	Arm's-length

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: **The Issuer is relying upon the customary representations and warranties under the Agreement. The Issuer has also completed due diligence.**
  
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.): **N/A**
  - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): \_\_\_\_\_
  - (b) Cash \_\_\_\_\_
  - (c) Securities \_\_\_\_\_
  - (d) Other \_\_\_\_\_
  - (e) Expiry date of any options, warrants etc. \_\_\_\_\_
  - (f) Exercise price of any options, warrants etc. \_\_\_\_\_

---

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

March 2023  
Page 7

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. N/A
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. N/A

### **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
  - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
  - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated April 15, 2024.

**Hugh Rogers**  
Name of Director or Senior  
Officer

*/s/Hugh Rogers*  
Signature

**CEO and Director**  
Official Capacity

---

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF  
LISTED SECURITIES**

March 2023  
Page 8



---

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF  
LISTED SECURITIES**

March 2023  
Page 9

## Appendix A

### PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

- 
- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.